Health

New blood test could help predict the severity of COVID-19 symptoms


During the height of the pandemic, some hospitals were overwhelmed with patients seeking treatment for COVID-19. This situation could happen again during future outbreaks, especially with SARS-CoV-2 variants of concern on the rise. Now, researchers reporting in ACS’ Analytical Chemistry have developed a blood test to predict which people infected with COVID-19 are most likely to experience serious symptoms, which could help health care workers prioritize patients for hospitalization and intensive care.

Although many people who contract COVID-19 have either no symptoms or mild ones, some require intensive care for pneumonia with acute respiratory distress syndrome. Risk factors for severe disease include older age, heart disease, cancer and diabetes, but these characteristics alone are not sufficient to predict which patients will become the sickest. Measuring levels of certain proteins or metabolites in the blood could help, but these tests are often slow, complicated or expensive. For more effective triage of COVID-19 patients at hospitals, Michelle Hill, Sanjeeva Srivastava and colleagues aimed to develop an easy-to-use method that could quickly and cost-effectively predict COVID-19 severity.

To measure changes in blood biochemistry that occur with severe COVID-19, the researchers chose a technique called attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR), which has been tested previously as a COVID-19 diagnostic tool. Two regions of FTIR spectra from 128 patient plasma samples showed small but observable differences between those with severe and non-severe COVID-19. Using these data together with clinical information about patients, the researchers developed a statistical model to predict COVID-19 severity. They found that the best predictor was whether the patient had diabetes, followed by the two regions in the FTIR spectra. Adding the FTIR data to the model improved the sensitivity for detecting severe disease in a different set of 30 patients from 41.2% to 94.1%, but reduced the specificity from 84.6% to 69.2%, compared with the clinical factors alone. This means that the new test was more likely to identify severe cases, but it also had a higher rate of false positives, than the clinical data alone. Although the strategy needs to be tested in larger numbers of patients, it shows promise as a rapid, simple and economic triaging test for hospitals, the researchers say.

Source:

Journal reference:

Banerjee, A., et al. (2021) Rapid Classification of COVID-19 Severity by ATR-FTIR Spectroscopy of Plasma Samples. Analytical Chemistry. doi.org/10.1021/acs.analchem.1c00596.

Most Related Links :
Business News Governmental News Finance News

Need Your Help Today. Your $1 can change life.

[charitable_donation_form campaign_id=57167]

Source link

Back to top button